News Archive

Positive topline results from the Phase III HERCULES study with caplacizumab

October 2, 2017 ABLYNX "announced positive topline results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)." View the full article.

Blood Donation

Pam shares her story

Walk to Answer TTP participant continues her awareness and fundraising for TTP. On September 22 Pam hosted a blood drive in Charlottetown. Pam has been participating in the annual Walk to Answer TTP Together since 2012. Thank you for your dedication to the cause Pam. Your efforts keep the conversation about TTP alive. Pam's story is available here.

Blood Donation

Ashlee shares her story

Ashlee bravely shares her story for a local blood drive. Ashlee will be walking with the Community on September 16, 2017 and is featured on this year's walk awareness poster. Thank you Ashlee for being such an active advocate for TTP. Together we will improve the prognosis for all those affected by TTP. Local news coverage here at ksby.com.

Foundation News

The Foundation is being restructured to focus volunteer resources. Marie has been the Foundation’s administrator over the past five years thanks to the support of the Unilock Group of Companies. Today will mark Marie’s last day in this role*. Marie is not going far; she will continue in a bookkeeping capacity.

Rare Disease Day February 28th

Today, events are occurring around the world to recognize rare diseases.   What a great time for you to get involved in supporting a rare disease by making a difference.  This year Rare Disease Day has created a theme around RESEARCH, with a slogan of 'With research, possibilities are limitless'.

Pages